Analyst Reco. Taysha Gene Therapies, Inc.

Equities

TSHA

US8776191061

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
2.57 ^USD	-0.39%		+7.53%	+45.20%

02/05	Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome	CI
09/04	Piper Sandler Initiates Taysha Gene Therapies at Overweight Rating With $9 Price Target	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Initiates Taysha Gene Therapies at Overweight Rating With $9 Price Target	09/04	MT
Chardan Adjusts PT on Taysha Gene Therapies to $7 From $5 as Gene Therapy for Rett Syndrome Shows 'Sustained Benefit', Keeps Buy Rating	21/03	MT
Needham Adjusts Taysha Gene Therapies Price Target to $7 From $5, Maintains Buy Rating	20/03	MT
Cantor Fitzgerald Adjusts Price Target on Taysha Gene Therapies to $7 From $6, Keeps Overweight Rating	15/11	MT
Truist Securities Adjusts Price Target on Taysha Gene Therapies to $5 From $6, Maintains Buy Rating	20/23/20	MT
Canaccord Genuity Adjusts Price Target on Taysha Gene Therapies to $6 From $7, Maintains Buy Rating	20/23/20	MT
North American Morning Briefing : Fed Seen Holding Rates, Powell Comments Key	20/23/20	DJ
Truist Securities Raises Price Target on Taysha Gene Therapies to $6 From $2, Maintains Buy Rating	15/23/15	MT
Baird Adjusts Price Target on Taysha Gene Therapies to $8 From $6, Maintains Outperform Rating	15/23/15	MT
Needham Adjusts Price Target on Taysha Gene Therapies to $5 From $6, Keeps Buy Rating	15/23/15	MT
Cantor Fitzgerald Adjusts Price Target on Taysha Gene Therapies to $7 From $2, Maintains Overweight Rating	14/23/14	MT
SMBC Nikko Trims Taysha Gene Therapies' Price Target to $2 From $3, Maintains Outperform Rating	30/23/30	MT
Morgan Stanley Adjusts Taysha Gene Therapies' Price Target to $1 From $3, Keeps Equalweight Rating	30/23/30	MT
Cantor Fitzgerald Adjusts Price Target on Taysha Gene Therapies to $2 From $13, Maintains Overweight Rating	30/23/30	MT
Chardan Trims Price Target on Taysha Gene Therapies to $5 From $6, Keeps Buy Rating	30/23/30	MT
BTIG Downgrades Taysha Gene Therapies to Neutral From Buy	02/23/02	MT
Canaccord Genuity Adjusts Taysha Gene Therapies' Price Target to $13 From $17, Keeps Buy Rating	01/23/01	MT
Chardan Adjusts Taysha Gene Therapies' Price Target to $6 From $16, Keeps Buy Rating	01/23/01	MT
Truist Securities Adjusts Taysha Gene Therapies' Price Target to $4 From $15, Keeps Buy Rating	01/23/01	MT
Needham Adjusts Taysha Gene Therapies' Price Target to $6 From $16, Keeps Buy Rating	01/23/01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Taysha Gene Therapies, Inc.

Equities

TSHA

US8776191061

Analyst Reco.

Filters